Companies OnKure Therapeutics, Inc.
OnKure Therapeutics (OKUR): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me OnKure Therapeutics, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $9,515,165FY2024
- $1,467,934FY2025
CEO total pay was $1,467,934 in fiscal 2025, down from $9,515,165 in fiscal 2024.
FY2025: salary $600,000 · bonus $0 · stock awards $0 · option awards $609,934
Order OKUR
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nicholas Saccomano | $600,000 | $0 | $0 | $609,934 | $247,500 | $0 | $10,500 | $1,467,934 |
| President and Chief Executive Officer | ||||||||
| Jason Leverone | 444,000 | 0 | 0 | 304,967 | 133,200 | 0 | 14,000 | 896,167 |
| Chief Financial Officer | ||||||||
| Samuel Agresta | 482,000 | 0 | 0 | 211,131 | 144,600 | 0 | 14,000 | 851,731 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Nicholas Saccomano | $1,467,934 | $9,515,165 | — | ↓ −8,047,231 |
| Jason Leverone | 896,167 | 2,678,570 | — | ↓ −1,782,403 |
| Samuel Agresta | 851,731 | 2,841,068 | — | ↓ −1,989,337 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Board and Compensation Committee recognize the importance of base salary as a fixed source of income to attract and retain NEOs, while using annual bonuses and equity awards to align executive interests with stockholder value creation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jason Leverone, C.P.A. | OPTION | — | — | — | 65,000 | — | $304,967 |
| Samuel Agresta, M.D. | OPTION | — | — | — | 45,000 | — | 211,131 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jason Leverone, C.P.A. | $0 | $0 | $304,967 | 0.0% |
| Samuel Agresta, M.D. | 0 | 0 | 211,131 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jason Leverone | Option | 121 | 21.2 | — |
| Saccomano | Option | 495 | 13.99 | — |
| Saccomano | RSU | 1,424 | — | 4,130 |
| Jason Leverone | Option | 1,774 | 13.99 | — |
| Jason Leverone | RSU | 5,105 | — | 14,805 |
| Samuel Agresta | Option | 10,069 | 13.99 | — |
| Samuel Agresta | Option | 34,688 | 5.19 | — |
| Jason Leverone | Option | 50,105 | 5.19 | — |
| Jason Leverone | Option | 79,818 | 18.2 | — |
| Samuel Agresta | Option | 80,298 | 18.2 | — |
| Saccomano | Option | 100,209 | 5.19 | — |
| Saccomano | Option | 331,364 | 18.2 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Andrew Phillips, Ph.DIndependent · Audit · Compensation (Chair) · Nominating and Corporate Governance (Chair) | $87,500 | $0 | $16,294 | — | $0 | $103,794 |
| Isaac Manke, Ph.DIndependent | 60,497 | 0 | 16,294 | — | 0 | 76,791 |
| R. Michael CarruthersIndependent · Audit (Chair) | 55,000 | 0 | 16,294 | — | 0 | 71,294 |
| Edward MathersIndependent · Audit · Compensation | 44,998 | 0 | 16,294 | — | 0 | 61,292 |
| Valerie M. Jansen, M.D., Ph.DIndependent · Nominating and Corporate Governance | 44,000 | 0 | 16,294 | — | 0 | 60,294 |
| Michael GreyIndependent | 40,000 | 0 | 16,294 | — | 0 | 56,294 |
| Nicholas SaccomanoEmployee director | — | — | — | — | — | 0 |
| Liam Ratcliffe, Ph.DIndependent · Newly elected | 0 | 0 | 0 | — | — | 0 |
| Dr. SaccomanoEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 5,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $331,995 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $331,995 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names OnKure Therapeutics as a peer
Companies that benchmark against OKUR
No companies currently name OKUR as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | OnKure Therapeutics, Inc. | 2025 | Nicholas Saccomano | $600,000 | $0 | $609,934 | $247,500 | $1,467,934 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (18 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Nicholas Saccomano. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 1,467,934. View filing ↗
- Section 01, Jason Leverone. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 896,167. View filing ↗
- Section 01, Samuel Agresta. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 851,731. View filing ↗
- Section 03, Jason Leverone, C.P.A. OPTION. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Samuel Agresta, M.D. OPTION. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Andrew Phillips, Ph.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 103,794. View filing ↗
- Section 08, Isaac Manke, Ph.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 76,791. View filing ↗
- Section 08, R. Michael Carruthers. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 71,294. View filing ↗
- Section 08, Edward Mathers. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 61,292. View filing ↗
- Section 08, Valerie M. Jansen, M.D., Ph.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 60,294. View filing ↗
- Section 08, Michael Grey. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 56,294. View filing ↗
- Section 08, Nicholas Saccomano. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Liam Ratcliffe, Ph.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Dr. Saccomano. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 331,995 + equity 0 + all other 0 = 331,995, summed across the director compensation table rows.
- OnKure Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in OnKure Therapeutics, Inc.'s own proxy. As printed: 1,467,934. View filing ↗